Alogliptin / Pioglitazone Uses, Dosage, Side Effects and Interactions
Oseni
Oseni was approved by the FDA in January 2013 as a tablet. The FDA rates no generic as a substitute for it.
Alogliptin / Pioglitazone is a two-in-one tablet taken by mouth, sold as Oseni and as generic alogliptin and pioglitazone, that helps control blood sugar in adults with type 2 diabetes along with diet and exercise.
Quick links
Ask Anything About Alogliptin / PioglitazoneType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Alogliptin / Pioglitazone in Short
- Drug classes Dipeptidyl Peptidase 4 Inhibitor; Peroxisome Proliferator-activated Receptor alpha Agonist; Peroxisome Proliferator-activated Receptor gamma Agonist; Thiazolidinedione How the FDA classifies it
What it treatsAlogliptin and pioglitazone tablets, including the brand Oseni, are used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. They are not recommended for people with type 1 diabetes.
- How you get it Prescription only
- Comes asTablet (by mouth)Available strengths (alogliptin/pioglitazone)
- 12.5 mg/30 mg
- 25 mg/15 mg
- 25 mg/30 mg
- 25 mg/45 mg
- Crushing or chewingSome forms are on our Do Not Crush list Listed: Alogliptin benzoate-pioglitazone hydrochloride (tablet); Oseni (tablet)
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
- What pharmacies pay
- Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it
The Pharmacist’s Take
Alogliptin/pioglitazone (Oseni) is a tablet for type 2 diabetes that pairs alogliptin, which boosts gut hormones that trigger insulin release after meals, with pioglitazone, which helps your body use its own insulin; it is usually an add-on rather than a first choice, on the market since about 2012 with FDA-approved generics listed. It is generally well tolerated; cold-like symptoms, back pain and mild ankle swelling are what people notice most. The boxed warning is heart failure, so report fast weight gain, shortness of breath or swelling in your legs right away, especially after starting or raising the dose. Expect a liver test before you start, plus regular eye exams.
Key Takeaways From the HelloPharmacist Team
- Take it once a day, with or without food, swallow it whole, and never double the next dose after a missed one.
- Expect the full blood sugar effect to build slowly over several weeks, because the pioglitazone half takes time to work.
- Stop the medicine and get medical care for severe stomach pain spreading to your back, a possible sign of an inflamed pancreas.
- Ask whether your plan covers an FDA-approved generic, since generics of this combination are listed alongside brand Oseni.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Alogliptin / Pioglitazone.
This medicine can cause or worsen congestive heart failure. Pioglitazone, one of its two ingredients, makes some people hold extra fluid.
Watch for fast weight gain, shortness of breath and swelling, especially after starting or raising the dose. Call your doctor right away if you notice these. It is not recommended if you have symptomatic heart failure, and it must not be started if you have NYHA Class III or IV heart failure.
Patient Information Guide for Alogliptin / Pioglitazone
What It’s Used For
This combination tablet is used for type 2 diabetes in adults.
- Alogliptin and Pioglitazone tablets and Oseni (oral tablets) are used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- They are not recommended for type 1 diabetes.
How It Works
Alogliptin is a DPP-4 inhibitor. It blocks an enzyme that breaks down incretin hormones, so those hormones last longer, help release insulin when blood sugar is high and lower the sugar made by the liver.
Pioglitazone is a thiazolidinedione. It lowers insulin resistance in your muscle, fat and liver so your own insulin works better. It does not make the pancreas release more insulin.
Drug Class
Drug Class
- Dipeptidyl Peptidase 4 Inhibitor from alogliptin
- Peroxisome Proliferator-activated Receptor alpha Agonist from pioglitazone
- Peroxisome Proliferator-activated Receptor gamma Agonist from pioglitazone
- Thiazolidinedione from pioglitazone
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class. Alogliptin / Pioglitazone has two active ingredients, so each class says which one it comes from.
Drug Class
Established Pharmacologic Class (EPC)- Dipeptidyl Peptidase 4 Inhibitor from alogliptin
- Peroxisome Proliferator-activated Receptor alpha Agonist from pioglitazone
- Peroxisome Proliferator-activated Receptor gamma Agonist from pioglitazone
- Thiazolidinedione from pioglitazone
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Dipeptidyl Peptidase 4 Inhibitors from alogliptin
- Peroxisome Proliferator-activated Receptor alpha Agonists from pioglitazone
- Peroxisome Proliferator-activated Receptor gamma Agonists from pioglitazone
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Alogliptin / Pioglitazone in the FDA’s index.
From our Patient Information GuideAlogliptin is a DPP-4 inhibitor. It blocks an enzyme that breaks down incretin hormones, so those hormones last longer, help release insulin when blood sugar is high and lower the sugar made by the liver. Pioglitazone is a thiazolidinedione. Read How Alogliptin / Pioglitazone Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)- Thiazolidinediones from pioglitazone
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Combinations of oral blood glucose lowering drugs
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Take one tablet by mouth once a day, with or without food. Do not split it.
Your prescriber chooses the strength based on your current diabetes medicines, kidney function and heart condition.
- If you miss a dose, do not take a double dose next time.
- Liver tests are done before you start, and kidney function is checked before and during treatment.
- The dose is limited if you take gemfibrozil or similar medicines.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Not treated with either alogliptin or pioglitazone, starting dosage
For adults not taking alogliptin or pioglitazone · Starting dose Starting dose 25 mg of alogliptin/15 mg or 25 mg/30 mg once a day Highest dose 25 mg of alogliptin and 45 mg of pioglitazone once a dayCurrently treated with alogliptin, starting dosage
For adults already taking alogliptin · Starting dose Starting dose 25 mg of alogliptin/15 mg or 25 mg/30 mg once a day Highest dose 25 mg of alogliptin and 45 mg of pioglitazone once a dayCurrently treated with pioglitazone, starting dosage
For adults already taking pioglitazone · Starting dose Starting dose 25 mg of alogliptin/15 mg, 25 mg/30 mg, or 25 mg/45 mg of pioglitazone once a day Highest dose 25 mg of alogliptin and 45 mg of pioglitazone once a day
Currently treated with alogliptin and pioglitazone, starting dosage
For adults already taking alogliptin and pioglitazone · Starting dose
Highest dose 25 mg of alogliptin and 45 mg of pioglitazone once a day
- Select a dosage that is as close as possible to the current dosage of alogliptin and pioglitazone
NYHA class I or II congestive heart failure, starting dosage
For adults · Starting dose
Starting dose 25 mg of alogliptin and 15 mg of pioglitazone
Good to know
Monitor for fluid retention; consider stopping or lowering pioglitazone if heart failure develops
Type 2 diabetes (blood sugar control)
For adults also taking gemfibrozil or similar medicines
Highest dose 25 mg of alogliptin and 15 mg of pioglitazone once a day
- Maximum 25 mg of alogliptin and 15 mg of pioglitazone once daily
Other Doses
Adults with moderate kidney problems Usual dose 12.5 mg of alogliptin and 30 mg of pioglitazone once a day
Good to know
Not recommended with severe renal impairment (CrCl ≥15 to <30 mL/min) or ESRD
CrCl means creatinine clearance, a measure of how well the kidneys work.
ESRD means end-stage renal disease (kidney failure).
Side Effects
The most common side effects in studies were:
Common side effects
- Stuffy or runny nose and sore throat (nasopharyngitis)
- Back pain
- Upper respiratory tract infection (cold-like symptoms)
- Swelling (edema), which can be dose-related
- Low blood sugar, especially with insulin or sulfonylurea medicines
When to get medical help
- Rapid weight gain, shortness of breath or swelling in your legs or feet, which can be signs of heart failure. Report these right away.
- Severe stomach pain that may spread to your back, with or without vomiting, which can be a sign of pancreatitis (inflamed pancreas). Stop the medicine and call your doctor.
- Swelling of the face, lips or throat, trouble breathing, or a severe skin reaction. These can be signs of a serious allergic reaction.
- Tiredness, loss of appetite, pain in the upper right belly, dark urine or yellow skin or eyes, which can signal liver problems.
- Blurred or changed vision, which can be a sign of macular edema (swelling in the back of the eye).
- Severe, disabling joint pain.
- Blisters or raw patches on the skin, which can be a sign of bullous pemphigoid.
- Bone fractures, which were more common in women taking pioglitazone.
Warnings and Precautions
- Heart failure (boxed warning): pioglitazone can cause or worsen it. Watch for fast weight gain, swelling and shortness of breath.
- Pancreatitis: stop the medicine if it is suspected.
- Serious allergic reactions: including anaphylaxis, angioedema and Stevens-Johnson syndrome.
- Liver problems: sometimes fatal liver failure has been reported.
- Fractures: more common in women taking pioglitazone.
- Bladder cancer: pioglitazone may raise the risk of bladder tumors, though studies disagree.
- Low blood sugar: more likely with insulin or sulfonylureas.
- Eye swelling, severe joint pain and blistering skin disease have also been reported.
Interactions
A few medicines can change how this tablet works or raise the risk of side effects.
- Gemfibrozil and other strong CYP2C8 inhibitors: raise pioglitazone levels, so the maximum dose is limited.
- Rifampin and other CYP2C8 inducers: may lower pioglitazone levels, so treatment may need adjusting.
- Topiramate: may lower pioglitazone levels, so blood sugar should be monitored.
- Insulin and sulfonylureas: raise the risk of low blood sugar, so their doses may need to be lowered.
Interactions Listed in the FDA-Approved Label
From the Alogliptin / Pioglitazone prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Insulin secretagogues (e.g., sulfonylurea) and insulinWhat happensKnown to cause hypoglycemia; combined use may require lower dosages of the secretagogue or insulin.What to doLower dosages of the insulin secretagogue or insulin may be needed to reduce the risk of hypoglycemia.
-
Strong CYP2C8 inhibitors For example: gemfibrozilWhat happensSignificantly increase pioglitazone exposure (AUC) and half-life.What to doMaximum 25 mg of alogliptin and 15 mg of pioglitazone once daily.
-
CYP2C8 inducers For example: rifampinWhat happensMay significantly decrease pioglitazone exposure (AUC).What to doIf an inducer is started or stopped, changes in diabetes treatment may be needed, without exceeding 25 mg of alogliptin and 45 mg of pioglitazone.
-
What happensDecreases exposure of pioglitazone and its active metabolites; clinical relevance unknown.What to doMonitor patients for adequate glycemic control.
Read the label’s full interactions text
7 DRUG INTERACTIONS Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations. Limit the pioglitazone dose to 15 mg daily. CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. Topiramate may decrease pioglitazone concentrations. 7.1 Insulin Secretagogues and Insulin Insulin and insulin secretagogues are known to cause hypoglycemia. Coadministration of alogliptin and pioglitazone tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower dosages of the insulin secretagogue and insulin to reduce the risk of hypoglycemia. 7.2 Strong CYP2C8 Inhibitors An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the concentration-time curve [AUC]) and half-life of pioglitazone. Therefore, the maximum recommended dosage of alogliptin and pioglitazone tablets is 25 mg of alogliptin and 15 mg of pioglitazone once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors. 7.3 CYP2C8 Inducers An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with alogliptin and pioglitazone tablets, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dose of alogliptin and pioglitazone tablets (25 mg of alogliptin and 45 mg of pioglitazone). 7.4 Topiramate A decrease in the exposure of pioglitazone and its active metabolites were noted with concomitant administration of pioglitazone and topiramate.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not use it if you have established NYHA Class III or IV heart failure, or a past serious allergy to alogliptin, pioglitazone or the tablet ingredients.
- Tell your prescriber about heart failure, swelling, kidney disease or liver disease.
- Tell your prescriber about active or past bladder cancer.
- Kidney function is checked first. Moderate kidney impairment needs a lower dose. It is not recommended for severe kidney disease or dialysis.
- Pregnancy: human data are limited, and poorly controlled diabetes carries its own risks. Premenopausal women should know pioglitazone may cause ovulation and an unintended pregnancy.
- Breastfeeding: no human milk data are available, so discuss it with your prescriber.
- Children: not recommended.
- Older adults: no overall differences in safety or effectiveness were seen.
Overdose
In an overdose, doctors provide supportive care and monitoring, and may remove unabsorbed drug from the stomach and intestines. Dialysis is unlikely to help. Call Poison Help at 1-800-222-1222 right away.
How Your Body Processes It
The combination tablet delivers both drugs similarly to taking them separately, and food does not significantly change absorption. Alogliptin is mostly cleared unchanged by the kidneys. Pioglitazone is broken down extensively in the liver, mainly by the CYP2C8 enzyme, into active metabolites. Steady levels of pioglitazone are reached within about seven days of daily use.
Storage
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) . Protect from moisture and humidity.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Alogliptin / Pioglitazone: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Alogliptin / Pioglitazone — the kind of thing our pharmacy team would talk through with you at the counter.
What is alogliptin / pioglitazone used for?
How do I take alogliptin / pioglitazone?
What happens if I miss a dose of alogliptin / pioglitazone?
What side effects should I expect, and which ones mean I should call?
Is alogliptin / pioglitazone safe if I have heart failure?
Does alogliptin / pioglitazone interact with other medicines?
Is alogliptin / pioglitazone available over the counter?
When was alogliptin / pioglitazone first available?
Who makes alogliptin / pioglitazone?
What is the brand name of alogliptin / pioglitazone?
What is the generic name of Oseni?
What drug class is alogliptin / pioglitazone?
Is there a generic version of alogliptin / pioglitazone?
What strengths does alogliptin / pioglitazone come in?
How much does alogliptin / pioglitazone cost?
Where can I read the alogliptin / pioglitazone prescribing information (package insert)?
Can you crush alogliptin / pioglitazone?
Is alogliptin / pioglitazone gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Alogliptin / Pioglitazone
Skip the scrolling. Ask in your own words and get an answer from Alogliptin / Pioglitazone’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Alogliptin / Pioglitazone’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Alogliptin / Pioglitazone on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Alogliptin / Pioglitazone Forms and Strengths (How It Comes)
Alogliptin / Pioglitazone comes in 1 dose form, the tablet. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Alogliptin / Pioglitazone inactive ingredients by manufacturer.
Tablet
How this form is used
- Alogliptin and Pioglitazone tablets are used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- Oseni is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- Oseni is taken by mouth once daily, with or without food.
- Oseni tablets should not be split.
- Alogliptin and Pioglitazone tablets are taken by mouth once daily, with or without food.
- With Alogliptin and Pioglitazone tablets, do not double the next dose if you miss one.
Alogliptin / Pioglitazone on the U.S. Market: Products, Makers and Brands
How Alogliptin / Pioglitazone appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
2 companies list 8 Alogliptin / Pioglitazone product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2012. The one brand name in the directory today is Oseni; the rest are generics.
Also listed with the FDA, not a patient dose form: Unfinished tablet, film coated (10) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Alogliptin / Pioglitazone Is Used (Medicaid Data)
How many Alogliptin / Pioglitazone prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Alogliptin / Pioglitazone prescribed? Of the 1,682 medications we measure, Alogliptin / Pioglitazone ranks #1,364 by Medicaid prescriptions — more than 19% of them.
Utilization by Alogliptin / Pioglitazone product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
alogliptin 25 MG / pioglitazone 30 MG Oral Tablet Most dispensed
1 of 6 listed NDCs had Medicaid claims. RxNorm 1368431
alogliptin 25 MG / pioglitazone 15 MG Oral Tablet
1 of 6 listed NDCs had Medicaid claims. RxNorm 1368424
alogliptin 25 MG / pioglitazone 45 MG Oral Tablet
1 of 6 listed NDCs had Medicaid claims. RxNorm 1368438
alogliptin 12.5 MG / pioglitazone 30 MG Oral Tablet
1 of 6 listed NDCs had Medicaid claims. RxNorm 1368410
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 4 of the 24 listed Alogliptin / Pioglitazone NDCs had Medicaid claims.
Compare Alogliptin / Pioglitazone Products
A representative set of FDA-listed product records for Alogliptin / Pioglitazone — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| ALOGLIPTIN BENZOATE 12.5 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 45 mg | Oral | Padagis Israel Pharmaceuticals Ltd | NDA AUTHORIZED GENERIC | View NDC → |
| ALOGLIPTIN BENZOATE 12.5 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | Oral | Takeda Pharmaceuticals America, Inc. | NDA | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg | Oral | Takeda Pharmaceuticals America, Inc. | NDA | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg | Oral | Takeda Pharmaceuticals America, Inc. | NDA | View NDC → |
| ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 45 mg | Oral | Takeda Pharmaceuticals America, Inc. | NDA | View NDC → |
Showing 8 of 8 products — FDA National Drug Code Directory. See every product, package size and price: browse all 8 Alogliptin / Pioglitazone NDCs →
Alogliptin / Pioglitazone Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Alogliptin / Pioglitazone — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Alogliptin / Pioglitazone in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Alogliptin / Pioglitazone FDA Approval History
How Alogliptin / Pioglitazone went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Alogliptin / Pioglitazone Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Alogliptin / Pioglitazone recalls since July 2021.
✅No Alogliptin / Pioglitazone recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Alogliptin / Pioglitazone in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one exact combination of ingredients (MIN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. A different combination is a different concept with its own page.
- Dose forms
- 1
- Strengths
- 6
- Forms in current FDA listings
- 1 of 1
RxCUI 1368402 -
Dose form (SCDF) Oral TabletIn current FDA listings
RxCUI 1368401Its 6 strengths (SCD)-
alogliptin 12.5 mg / pioglitazone 15 mg
RxCUI 1368403 -
alogliptin 12.5 mg / pioglitazone 30 mg
RxCUI 1368410 -
alogliptin 12.5 mg / pioglitazone 45 mg
RxCUI 1368417 -
alogliptin 25 mg / pioglitazone 15 mg
RxCUI 1368424 -
alogliptin 25 mg / pioglitazone 30 mg
RxCUI 1368431 -
alogliptin 25 mg / pioglitazone 45 mg
RxCUI 1368438
-
alogliptin 12.5 mg / pioglitazone 15 mg
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Alogliptin / Pioglitazone Supply and Shortage Status
Whether Alogliptin / Pioglitazone is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Alogliptin / Pioglitazone Costs Pharmacies (NADAC Benchmark)
What pharmacies pay to buy Alogliptin / Pioglitazone: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.
How the Pharmacy Price Has Changed
Pick a strength to see how its price has changed since Jul 2024.
For the generic ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg tablet, pharmacies paid an average of $4.73 per tablet as of Nov 18, 2026, down 14% from $5.52 a year earlier.
- What pharmacies pay now
- $4.73
- per tablet, as of Nov 18, 2026
- Last 4 weeks
- No change
- from $4.73 on Oct 21, 2026
- Last 12 months
- Down 14%
- from $5.52 on Nov 19, 2025
- Lowest and highest since Jul 2024
- $4.73 to $5.52
- per tablet
See the numbers, month by month
| Month | Pharmacy price |
|---|---|
| Nov 2026 | $4.73 |
| Oct 2026 | $4.73 |
| Sep 2026 | $4.73 |
| Dec 2025 | $5.52 |
| Nov 2025 | $5.52 |
| Oct 2025 | $5.52 |
| Sep 2025 | $5.52 |
| Aug 2025 | $5.52 |
| Jul 2025 | $5.52 |
| Jun 2025 | $5.52 |
| May 2025 | $5.52 |
| Apr 2025 | $5.52 |
| Mar 2025 | $5.52 |
| Feb 2025 | $5.52 |
| Jan 2025 | $5.52 |
| Dec 2024 | $5.52 |
| Nov 2024 | $5.52 |
| Oct 2024 | $5.52 |
| Sep 2024 | $5.42 |
| Aug 2024 | $5.42 |
| Jul 2024 | $5.31 |
| Form | Strength | Version | What pharmacies pay | |
|---|---|---|---|---|
| Tablet · Oral | ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg | Generic | $4.73 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.
Alogliptin / Pioglitazone Brand Names
Alogliptin / Pioglitazone has one brand name on record: Oseni. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Alogliptin / Pioglitazone: Manufacturers and Labelers
2 companies list Alogliptin / Pioglitazone products with the FDA. By number of product records, the largest are Padagis Israel Pharmaceuticals Ltd, Takeda Pharmaceuticals America, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Alogliptin / Pioglitazone Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Padagis Israel Pharmaceuticals Ltd is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →